Breaking News

Leading BioSciences Drug May Help Critical COVID-19 Patients

Investigational drug, LB1148, being considered to treat respiratory distress and organ dysfunction in critically ill COVID-19 patients

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Leading BioSciences, a drug development company, has developed a potential approach to treat COVID-19 patients with acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) using its investigational drug LB1148. Studies in the New England Journal of Medicine report 70% of critically ill COVID-19 patients experienced a shock/hypotension. A case fatality rate of 49% or higher is reported for COVID-19 patients who develop respiratory failure, septic shock, or MOD...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters